Rite Bio Sciences (Pvt) Ltd.
Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.
Private pharmaceutical registration holder / marketer · Rawat · Pakistan
Rawat/Islamabad pharmaceutical registration holder represented in current DRAP product records, with some products manufactured under contract.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Rite Bio Sciences (Pvt.) Ltd.
- Company type
- Private pharmaceutical registration holder / marketer
- Address
- Plot No. 9-A, Street N-5, RCCI, Rawat, Islamabad, Pakistan
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 50%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Brodsef | Cefixime | 400 mg | Capsule | 5's | 087647 | PKR 596.33 | PKR 119.27/capsule | 6% above median |
| Brodsef | Cefixime | 100 mg/5 mL | Suspension | 30ml | 087648 | PKR 332.79 | PKR 11.09/mL | 6% above median |
| Curofloxin | Ciprofloxacin | 500 mg | Tablet | 10's | 087634 | PKR 420.45 | PKR 42.05/tablet | Near median |
| Curofloxin | Ciprofloxacin | 250 mg | Tablet | 10's | 087635 | PKR 254.22 | PKR 25.42/tablet | Near median |
| Curofloxin | Ciprofloxacin | 250 mg/5 mL | Suspension | 60ml | 109288 | PKR 312.89 | PKR 5.21/mL | Near median |
| Curofloxin | Ciprofloxacin | 250 mg/5 mL | Suspension | 120ml | 109288 | PKR 469.34 | PKR 3.91/mL | 24% below median |
| Doxlef | Levofloxacin | 250 mg | Tablet | 10's | 103567 | PKR 488.89 | PKR 48.89/tablet | Near median |
| Doxlef | Levofloxacin | 500 mg | Tablet | 10's | 103568 | PKR 813.52 | PKR 81.35/tablet | Near median |
| Eglence 25mg TabletRegistry verified | SILDENAFIL CITRATE equivalent to SILDENAFIL | — | — | — | 136818Official source ↗ | No indexed price | — | — |
| Esogerd 40mg InjectionRegistry verified | Esomeprazole as sodium | — | — | — | 131097Official source ↗ | No indexed price | — | — |
| Falxatin | Fluoxetine | 20 mg | Capsule | 10's | 087646 | PKR 127.11 | PKR 12.71/capsule | Near median |
| Kadrol 100mg/2ml InjectionRegistry verified | Tramadol HCl. | — | — | — | 137062Official source ↗ | No indexed price | — | — |
| Kadrol-P 37.5/325mg TabletRegistry verified | Paracetamol, Tramadol HCl | — | — | — | 137064Official source ↗ | No indexed price | — | — |
| Kadrol-P 75/650mg TabletRegistry verified | PARACETAMOL, Tramadol HCl. | — | — | — | 137063Official source ↗ | No indexed price | — | — |
| Letrite 2.5mg TabletsRegistry verified | Letrozole | — | — | — | 137065Official source ↗ | No indexed price | — | — |
| Nepix-E 375mg/20mg TabletRegistry verified | Esomeprazole as Magnesium Trihydreate, Naproxen | — | — | — | 135503Official source ↗ | No indexed price | — | — |
| Nepix-E 500mg/20mg TabletRegistry verified | Esomeprazole as Magnesium Trihydreate, Naproxen | — | — | — | 135502Official source ↗ | No indexed price | — | — |
| Orie | Hydroxychloroquine | 200 mg | Tablet | 50's | 109374 | PKR 880.01 | PKR 17.60/tablet | 22% above median |
| Orie | Hydroxychloroquine | 200 mg | Tablet | 30's | 109374 | PKR 528.00 | PKR 17.60/tablet | 22% above median |
| Ozapine Flash 10mg Orodispersible TabletsRegistry verified | Olanzapine | — | — | — | 136777Official source ↗ | No indexed price | — | — |
| Pepser | Omeprazole | 40 mg | Capsule | 14's | 087643 | PKR 488.89 | PKR 34.92/capsule | Near median |
| PepserSource observed | Omeprazole enteric coated pellets | 20 mg | Capsule | 14's | 087644Official source ↗ | No indexed price | — | — |
| Pepser 40mg InjectionRegistry verified | Omeprazole as sodium | — | — | — | 131096Official source ↗ | No indexed price | — | — |
| Pepser Insta 20mg/1680mg SachetRegistry verified | Omeprazole , Sodium bicarbonate | — | — | — | 135670Official source ↗ | No indexed price | — | — |
| Pepser Insta 40mg/1680mg SachetRegistry verified | Omeprazole , Sodium bicarbonate | — | — | — | 135671Official source ↗ | No indexed price | — | — |
| Pepser Plus 20mg/1100mg CapsuleRegistry verified | Omeprazole , Sodium bicarbonate | — | — | — | 136662Official source ↗ | No indexed price | — | — |
| Retabin | Capecitabine | 500 mg | Tablet | 120's | 128865 | PKR 41,820.92 | PKR 348.51/tablet | Near median |
| Revibort | Bortezomib | 3.5 mg/mL | Lyophilized powder for injection | 1's | 128832 | PKR 53,553.38 | PKR 53,553.38/vial/unit | No comparator |
| Rossoaiz | Azithromycin | 250 mg | Capsule | 6's | 102697 | PKR 299.20 | PKR 49.87/capsule | Near median |
| Rossoaiz | Azithromycin | 200 mg/5 mL | Oral suspension | 15ml | 102698 | PKR 322.67 | PKR 21.51/mL | 11% above median |
| Rossoaiz | Azithromycin | 250 mg | Tablet | 6's | 107076 | PKR 293.34 | PKR 48.89/tablet | Near median |
| Rossoaiz | Azithromycin | 500 mg | Tablet | 6's | 109373 | PKR 537.78 | PKR 89.63/tablet | 6% above median |
| Selfzin | Sulfasalazine | 500 mg | Tablet | 100's | 101820 | PKR 782.23 | PKR 7.82/tablet | Near median |
| Stroflox | Moxifloxacin | 400 mg | Tablet | 5's | 110594 | PKR 928.90 | PKR 185.78/tablet | Near median |
| Trisna 40mg/5ml Dry SuspensionRegistry verified | FAMOTIDINE | — | — | — | 137066Official source ↗ | No indexed price | — | — |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.